Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children
The clearance expands Dexcom's Stelo Glucose Biosensor System to users aged two and older who do not use insulin, while FDA warns it is not designed for problematic hypoglycemia alerts.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The US Food and Drug Administration cleared Dexcom Inc.'s Stelo Glucose Biosensor System on 12 June as the first over-the-counter continuous glucose monitor for children.
The integrated continuous glucose monitor is indicated for people two years of age and older who do not use insulin. FDA previously cleared Stelo for over-the-counter use in adults aged 18 and older in March 2024.
The system uses a wearable sensor paired with a smartphone or compatible smart-device app, including a caregiver device, to measure, record, analyse and display glucose values. FDA says the app displays measurements and trends every 15 minutes and that each sensor can last up to 15 days, although wear time may be shorter in pediatric users.
FDA says the clearance used prior clinical study data from pediatric and adult users as well as real-world evidence from current integrated CGM use to understand expected performance across the wear period.
The agency also set clear guardrails. Children should use the device under adult caregiver supervision, users should consult a healthcare provider before medication changes, and Stelo is not for people with problematic hypoglycemia because it is not designed to alert users to low blood sugar. FDA also says it is not for people on dialysis, and people with a history of disordered eating or eating disorders should speak with a healthcare provider before use.
Sourcing note: The clearance, indication, device limitations, real-world-evidence statement and reported mild adverse events are confirmed by FDA. Public-health impact and access benefits are FDA and manufacturer-facing regulatory claims, not independent outcome data.
Why It Matters
The clearance pushes continuous glucose monitoring further into home and caregiver settings, including children who are not using insulin. That could improve day-to-day awareness of glucose patterns, but it also makes warnings and intended use central: an over-the-counter device that does not provide low-glucose alerts is not a substitute for clinical supervision in higher-risk diabetes care.
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDADexcomContinuous Glucose MonitorPediatricsMedical Devices